Veradermics (MANE) CEO Reid Waldman highlights positive Phase 3 data for VDPHL01, its oral treatment candidate for male and female pattern hair loss. More than 80% of patients showed visible improvement, with some seeing benefits as early as two months. With $820 million in cash and runway into 2030, Veradermics is preparing for additional long-term and female Phase 3 data as it moves toward a potential FDA filing and commercial launch.